Lisa Moore-Ramdin, MBBS, MRCPCH, DPM, FFPM

Senior Director, Global Medical and Scientific Affairs Lead
Jazz Pharmaceuticals, United Kingdom

Poster(s):

• (57) Tuberous sclerosis complex–associated neuropsychiatric disorders (TAND) outcomes following adjunctive cannabidiol (CBD) treatment: 3-month analysis of the open-label phase 3b/4 trial EpiCom
  Wednesday, October 29, 2025